Akebia Therapeutics (AKBA) CEO exercises 350,000 stock options at $0.63
Rhea-AI Filing Summary
Akebia Therapeutics, Inc. CEO and President John P. Butler reported exercising stock options for 350,000 shares of common stock on August 6, 2026 at an exercise price of $0.63 per share. The derivative option position was reduced by 350,000 shares, leaving 525,000 options outstanding after the transaction. Following the exercise, Butler directly held 3,718,564 shares of common stock and indirectly held 159,928 shares through the Dorothy Butler Revocable Trust. The options were granted on January 31, 2023 and vest over four years, with 25% vested on January 31, 2024 and the remaining 75% vesting in equal quarterly installments thereafter.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 350,000 shares
Net Buy
3 txns
Insider
Butler John P.
Role
CEO and President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to buy) F2 | 350,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 350,000 | $0.63 | $221K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to buy) — 525,000 shares (Direct);
Common Stock — 3,718,564 shares (Direct);
Common Stock — 159,928 shares (Indirect, Held by Dorothy Butler Revocable Trust November 20, 2007)
Footnotes (2)
- F1. Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2026 under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
- F2. The options were granted by the Issuer on January 31, 2023 and vest over four years: 25% of the options vested on January 31, 2024 with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
Key Figures
Options Exercised: 350,000 shares
Exercise Price: $0.63 per share
Direct Holdings After: 3,718,564 shares
+3 more
6 metrics
Options Exercised
350,000 shares
Stock options exercised into common stock on August 6, 2026
Exercise Price
$0.63 per share
Exercise price for 350,000 stock options
Direct Holdings After
3,718,564 shares
Common stock directly held by John P. Butler after exercise
Remaining Options
525,000 shares
Stock options remaining after exercising 350,000 options
Indirect Holdings
159,928 shares
Common stock held through Dorothy Butler Revocable Trust
Option Expiration
2033-01-31
Expiration date of the stock options exercised
Key Terms
Stock Option (Right to buy), Exercise or conversion of derivative security, Amended and Restated 2014 Employee Stock Purchase Plan, Revocable Trust
4 terms
Stock Option (Right to buy) financial
"security_title: Stock Option (Right to buy)"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
Amended and Restated 2014 Employee Stock Purchase Plan financial
"purchased on June 30, 2026 under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan"
Revocable Trust financial
"Held by Dorothy Butler Revocable Trust November 20, 2007"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Akebia Therapeutics (AKBA) CEO John P. Butler report in this Form 4?
John P. Butler reported exercising stock options for 350,000 shares of Akebia Therapeutics common stock at $0.63 per share on August 6, 2026, increasing his directly held common stock position.
What stock options did the Akebia Therapeutics (AKBA) CEO exercise and at what price?
Butler exercised 350,000 stock options, each giving the right to buy Akebia Therapeutics common stock at an exercise price of $0.63 per share. These options were originally granted on January 31, 2023.
How many Akebia Therapeutics (AKBA) options remain after John P. Butler’s exercise?
After exercising 350,000 options, Butler has 525,000 stock options remaining. These options were granted on January 31, 2023 and continue to vest in equal quarterly installments over four years.
What is the vesting schedule of the Akebia Therapeutics (AKBA) options exercised by the CEO?
The options were granted on January 31, 2023. 25% vested on January 31, 2024, and the remaining 75% vest in equal quarterly installments, contingent on Butler’s continued service with Akebia Therapeutics.